National Consortium for Intelligent Medical Imaging

NCIMI is funded by the UK Government’s Industrial Strategy Challenge Fund to drive innovation in the use of artificial intelligence (AI) for improved diagnosis and delivery of precision treatments for cancer, heart disease, genetic disorders and other conditions. 

NCIMI aims to build a pipeline for innovation to allow new clinical imaging AI tools to be developed, tested, validated and adopted into the NHS. Clinical imaging already plays a significant role in the delivery of personalised care and earlier diagnosis, supporting improved disease outcomes. NCIMI will enable the rapid integration of novel AI tools into standard practice ensuring full patient benefit is extracted from existing imaging tools such as MRI, CT, PET-CT, and X-Ray. Some of the key cancer projects NCIMI supports are:

  • Characterisation of pulmonary nodules in patients with extra-thoracic malignancies; distinguishing benign from malignant nodules, and primary lung cancers from metastases;
  • Improved PET-CT reconstruction techniques, that will enable improved tumour detection and quantification of tumour metabolism;
  • Identification and characterisation of metastatic disease on spine MRI.

Led from Oxford’s Big Data Institute, the consortium is a national cloud-connected network bringing together necessary expertise across NHS (including 15 NHS Hospital Trusts*), academia, industry such as GE Healthcare, Alliance Medical, The Behavioural Architects and 7 Oxford University spin-outs+, as well as patient groups.
The Consortium is led by Prof Fergus Gleeson, Prof Sir Mike Brady, Prof Jim Davies and Prof Mike Parker. Further collaborators within Oxford include Prof Stefan Neubauer and Prof Charalambos Antoniades (RDM), Prof Gil McVean (BDI/NDM), Martin Landray (BDI/NDPH) and Alison Noble (IBME).
NCIMI is keen to expand and bring in new partnerships as it develops.

To stay up-to-date with NCIMI news, follow the consortium on Twitter.